Estrogen: Effects on the cardiovascular tree

Obstetrics and Gynecology

Volumn 87, Issue 2 II SUPPL., 1996, Pages

  Wild, Robert A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR; CONJUGATED ESTROGEN; ENDOTHELIUM DERIVED RELAXING FACTOR; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NORETHISTERONE ACETATE; SEX HORMONE; VERY LOW DENSITY LIPOPROTEIN;

ARTERY TONE; ATHEROSCLEROSIS; BLOOD CLOTTING; DIABETES MELLITUS; DRUG EFFECT; DRUG MIXTURE; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0030071198     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(95)00434-3     Document Type: Article

References (70)

1. Becker RC. Coronary heart disease in women: Risks and prevention. Coron Acute Care 1992;3:2-10.
2. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questions. Am Heart J 1987;114:1467-503.
3. Mortality statistics from the Washington State Department of Health. Center for Health Statistics, 1992.
4. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
5. Moliterno DJ, Lange RA, Meidell RS, et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 1993;88:935-40.
6. Hamsten A. Hemostatic function and coronary artery disease. N Engl J Med 1995;332:677-8.
7. Yao S-K, Ober JC, McNatt J, et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992;70:39-48.
8. Fal E. Why do plaques rupture? Circulation 1992;86(6 suppl):III-30-42.
9. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87: 1781-91.
10. Wissler RW, Vesselinovitch D. Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animal models. Am J Cardiol 1990;65:33F-40F.
11. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb 1994;14:177-92.
12. Pick R, Stamler J, Rodbard S, Katz LN. The inhibition of coronary atherosclerosis by estrogen in cholesterol-fed chicks. Circulation 1952;6:276-80.
13. Stamler J, Pick R, Katz LN. Prevention of coronary atherosclerosis by estrogen-androgen administration in the cholesterol-fed chick. Circ Res 1953;194-8.
14. Adams MR, Kaplan JR, Koritnik DR, Clarkson TB. Pregnancy-associated inhibition of coronary artery atherosclerosis in monkeys: Evidence of a relationship with endogenous estrogen. Arteriosclerosis 1987;7:378-83.
15. Pick R, Stamler J, Rodbard S, Katz LN. Estrogen-induced regression of coronary atherosclerosis in cholesterol-fed chicks. Circulation 1952;6:858-61.
16. Knopp RH. Estrogen replacement therapy for reduction of cardiovascular risk in women. Curr Opin Lipidol 1991;2:240-7.
17. Knopp RH, Zhu X-D, Lau J, Walden C. Sex hormones and lipid interactions: Implications for cardiovascular disease in women. Endocrinologist 1994;4:286-301.
18. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: Impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause: Physiology and pharmacology. Chicago: Year Book Medical Publishers, 1987:187-208.
19. Lobo RA. Estrogen and cardiovascular disease. Ann NY Acad Sci 1990;592:286-94.
20. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308: 862-7.
21. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement therapy on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
22. Sarrel PM. Ovarian hormones and the circulation. Maturitas 1990; 12:287-98.
23. Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens and lipoproteins, high density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol 1991;77:235-40.
24. Wahl PW, Walden CE, Knopp RH, Wallace R, Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862.
25. Applebaum-Bowden D, McLean P, Steinmetz A, et al. Lipoprotein. apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 1989;30: 1895-906.
26. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7.
27. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women Arch Intern Med 1994;154: 1333-9.
28. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate: A two-year follow-up study. Hypertension 1995;25:848-53.
29. Kayan AR, Sternby NH, Uemura K, et al. Atherosclerosis of the aorta and coronary arteries in five towns. Bull WHO 1976;53:485-653.
30. Ley CJ, Lees B, Stevenson JC. Sex-and-menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992;55:950-4
31. Walden CD, Knopp RH, Wahl PW, Beach KW, Strandness DE Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984;311: 953-9.
32. Knopp RH, Zhu X, Bonet B. Effects of estrogens on lipoprotein metabolism and cardiovascular disease in women. Atherosclerosis 1994;110(suppl):S83-91.
33. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healths women. Eur J Clin Invest 1993; 23:466-73.
34. Stevenson JC, Crook D, Godsland EF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Drugs 1994;47(suppl 2):35-41
35. Patsch JR. Triglyceride-rich lipoproteins and atherosclerosis. Atherosclerosis 1994;110(suppl):S23-6.
36. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75.
37. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. JAMA 1995;273:199-208.
38. Keaney JF Jr, Shwaery GT, Xu A, et al. 17β-Estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994;89: 2251-9.
39. Négre-Salvayre A, Pieraggi MT, Mabile L, Salvayre R. Protective effect of 17β-estradiol against the cytotoxicity of minimally oxidized LDL to cultured bovine aortic endothelial cells. Atherosclerosis 1993;99:207-17.
40. Steinbrecher UP. Role of lipoprotein peroxidation in the pathogenesis of atherosclerosis. Clin Cardiol 1991;14:865-7.
41. Sullivan JM, Zwaag RV, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988;108:358-63.
42. Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction: A conclusion derived from the study of 'preinfarction' angina. N Engl J Med 1978;299:1271-7.
43. Chierchia S, Brunelli C, Simonetti I, Lazzari M, Maseri A. Sequence of events in angina at rest: Primary reduction in coronary flow. Circulation 1980;61:759-68.
44. DeServi S, Specchia G, Ardissino D, et al. Angiographic demonstration of different pathogenetic mechanisms in patients with spontaneous and exertional angina associated with S-T segment depression. Am J Cardiol 1980;45:1285-91.
45. Maseri A, Mimmo R, Chierchia S, Marchesi C, Pesola A, L'Abbate A. Coronary artery spasm as a cause of acute myocardial ischemia in man. Chest 1974;68:625-33.
46. Neill WA, Wharton TP, Fluri-Lundeen J, Cohen IS. Acute coronary insufficiency-coronary occlusion after intermittent ischemic attacks. N Engl J Med 1980;302:1157-62.
47. Maseri A, Sevri P, Marzulla P. Role of coronary arterial spasm in sudden coronary ischemic death. Ann NY Acad Sci 1982;382:204-16.
48. Zeiher AM, Schächinger, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Circulation 1994;89:2525-32.
49. Heistad DD, Armstrong ML. Sick vessel syndrome: Can atherosclerotic arteries recover? Circulation 1994;89:2447-50.
50. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;228:373-6.
51. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991;83:391-401.
52. Dimario C, Strikwerda S, Gil R, Defeyter PJ, Dejaegere P, Serruys PW. Response of conductance and resistance coronary vessels to scalar concentrations of acetylcholine - assessment with quantitative angiography and intracoronary Doppler echography in 29 patients with coronary artery disease. Am Heart J 1994;127:514-31.
53. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest 1989;83:1946-52.
54. Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991;325:1551-6.
55. Williams JK, Shively CA, Clarkson TB. Determinants of coronary artery reactivity in premenopausal female cynomolgus monkeys with diet-induced atherosclerosis. Circulation 1994;90:983-7.
56. Adams MR, Kaplan JR, Clarkson TB, Koritnik DR. Ovariectomy, social status, and atherosclerosis in cynomolgus monkeys. Arteriosclerosis 1985;5:192-200.
57. Reis SE, Cloth SG, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
58. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-51.
59. Rosano GMC, et al. Estrogen improves exercise-induced myocardial ischemia in female patients with coronary artery disease. Lancet 1993;342:133-6.
60. Van Buren GA, Yang D, Clark KE. Estrogen-induced uterine vasodilatation is antagonized by L-netroarginine methyl ester, an inhibitor of nitric oxide synthesis. Am J Obstet Gynecol 1992;67: 828-33.
61. Jiang C, Sarrel PM, Poole-Wilson PA, Collins P. Acute effect of 17β-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992;263:H271-5.
62. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol 1991;104:1033-7.
63. Chang W-C, Nakao J, Orimo J, Murota S-I. Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture. Biochim Biophys Acta 1980;619:107-18.
64. Mäkilä U-M, Wahlberg L, Vlinikka L, Ylikorkala O. Regulation of prostacyclin and thromboxane production by human umbilical vessels: The effect of estradiol and progesterone in a superfusion model. Prostaglandins Leukot Med 1982;8:115-24.
65. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10.
66. Armstrong ML, Warner E, Connor W. Regression of coronary atheromatosis in rhesus monkeys. Circ Res 1970;27:59-67.
67. The Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. I: Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
68. Sarrel PM, Lufkin EG, Oursler MJ, Keefe D. Estrogen actions in arteries, bone, and brain. Sci Am Sci Med 1994;1:44-53.
69. Wild RA, Taylor EL, Knehans A. The gynecologist and the prevention of cardiovascular disease. Am J Obstet Gynecol 1995;172: 1-13.
70. Wild RA, Taylor EL, Knehans A, Cleaver V. Matriarchal model for cardiovascular prevention. Obstet Gynecol Surv 1994;49:147-52.